These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
183 related items for PubMed ID: 8836892
21. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Hepatology; 1996 Apr; 23(4):676-87. PubMed ID: 8666317 [Abstract] [Full Text] [Related]
22. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M. J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828 [Abstract] [Full Text] [Related]
26. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy. García-Bengoechea M, Basaras M, Barrio J, Arrese E, Montalvo II, Arenas JI, Cisterna R. Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257 [Abstract] [Full Text] [Related]
27. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. Arase Y, Suzuki F, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Kobayashi M, Sezaki H, Ikeda K, Kumada H. Intervirology; 2004 Jul; 47(1):19-25. PubMed ID: 15044832 [Abstract] [Full Text] [Related]
28. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Féray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, Reynès M, Bismuth H. Hepatology; 1995 Oct; 22(4 Pt 1):1084-9. PubMed ID: 7557855 [Abstract] [Full Text] [Related]
30. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S. Hepatology; 1993 Dec; 18(6):1319-25. PubMed ID: 8244255 [Abstract] [Full Text] [Related]
31. [Long-term therapy in chronic hepatitis C with recombinant alpha interferon]. Siciliano R, Trovato BA, Romano M, Pantò A, Seminara G, Malaguarnera M. Riv Eur Sci Med Farmacol; 1994 Dec; 16(3-4):73-8. PubMed ID: 7480963 [Abstract] [Full Text] [Related]
32. Host and viral characteristics affecting the response to interferon therapy in chronic hepatitis C. Laurent-Puig P, Dussaix E, Altman C, Laval C, Stuyver L, Wilber JC, Babany G, Chopineau S, Bedossa P, Brocheriou I. Eur J Gastroenterol Hepatol; 1995 Apr; 7(4):335-40. PubMed ID: 7541297 [Abstract] [Full Text] [Related]
33. Effectiveness of relative low-dose interferon treatment for patients with chronic hepatitis C. Hayashi J, Kishihara Y, Tani Y, Yamaji K, Nakashima K, Ikematsu H, Kashiwagi S. Fukuoka Igaku Zasshi; 1994 Jul; 85(7):211-8. PubMed ID: 8070751 [Abstract] [Full Text] [Related]
34. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. Hepatology; 1996 Apr; 23(4):695-9. PubMed ID: 8666319 [Abstract] [Full Text] [Related]
35. Predictive factors for efficacy of interferon therapy in chronic hepatitis type C. Ishibashi K, Kashiwagi T, Ito A, Tanaka Y, Nagata T, Tamaki J, Azuma M, Kishida Y, Yoshida A, Hikiji AY. Hepatogastroenterology; 1995 Apr; 42(5):535-41. PubMed ID: 8751211 [Abstract] [Full Text] [Related]
36. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study. Castilla A, Camps-Bansell J, Civeira MP, Prieto J. Am J Gastroenterol; 1993 Feb; 88(2):233-9. PubMed ID: 8424427 [Abstract] [Full Text] [Related]
37. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F. Hepatology; 1995 Mar; 21(3):645-9. PubMed ID: 7875661 [Abstract] [Full Text] [Related]
38. [Long-term treatment of cryptogenic hepatitis C using recombinant interferon alpha]. Hopf U, Möller B, König V, Küther S, Lobeck H, Huhn D. Z Gastroenterol; 1990 Sep; 28(9):453-7. PubMed ID: 2125776 [Abstract] [Full Text] [Related]
39. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y. Hepatology; 1995 Feb; 21(2):291-7. PubMed ID: 7843696 [Abstract] [Full Text] [Related]
40. [Chronic viral hepatitis due to the hepatitis C virus (HCV): treatment experience with lymphoblast interferon-alpha]. Foti G, De Cicco M, Masseo A, Mangano C, Tripodi A, Foti N. Minerva Med; 1996 Feb; 87(1-2):53-5. PubMed ID: 8610026 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]